Patterns of etanercept use in juvenile idiopathic arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry.
Arthritis, Juvenile
/ diagnosis
Child
Clinical Protocols
Drug Monitoring
/ methods
Drug Therapy, Combination
/ methods
Duration of Therapy
Etanercept
/ administration & dosage
Female
Humans
Immunosuppressive Agents
/ administration & dosage
Male
Medication Therapy Management
/ statistics & numerical data
Methotrexate
/ administration & dosage
Registries
/ statistics & numerical data
Tumor Necrosis Factor Inhibitors
/ administration & dosage
United States
/ epidemiology
Anti-TNF
Arthritis, juvenile
Cohort studies
Etanercept
Paediatric rheumatology
Registry
Journal
Pediatric rheumatology online journal
ISSN: 1546-0096
Titre abrégé: Pediatr Rheumatol Online J
Pays: England
ID NLM: 101248897
Informations de publication
Date de publication:
21 Aug 2021
21 Aug 2021
Historique:
received:
18
05
2021
accepted:
31
07
2021
entrez:
22
8
2021
pubmed:
23
8
2021
medline:
11
1
2022
Statut:
epublish
Résumé
We aimed to characterize etanercept (ETN) use in juvenile idiopathic arthritis (JIA) patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry. The CARRA Registry is a convenience cohort of patients with paediatric onset rheumatic diseases, including JIA. JIA patients treated with ETN for whom the month and year of ETN initiation were available were included. Patterns of ETN and methotrexate (MTX) use were categorized as follows: combination therapy (ETN and MTX started concurrently), step-up therapy (MTX started first and ETN added later), switchers (MTX started and then stopped when or before ETN started), MTX add-on (ETN started first and MTX added later), and ETN only (no MTX use). Data were described using parametric and non-parametric statistics as appropriate. Two thousand thirty-two of the five thousand six hundred forty-one patients with JIA met inclusion criteria (74% female, median age at diagnosis 6.0 years [interquartile range 2.0, 11.0]. Most patients (66.9%) were treated with a non-biologic disease modifying anti-rheumatic drug (DMARD), primarily MTX, prior to ETN. There was significant variability in patterns of MTX use prior to starting ETN. Step-up therapy was the most common approach. Only 34.0% of persistent oligoarticular JIA patients continued treatment with a non-biologic DMARD 3 months or more after ETN initiation. ETN persistence overall was 66.3, 49.4, and 37.3% at 24, 36 and 48 months respectively. ETN persistence among spondyloarthritis patients (enthesitis related arthritis and psoriatic JIA) varied by MTX initiation pattern, with higher ETN persistence rates in those who initiated combination therapy (68.9%) and switchers/ETN only (73.3%) patients compared to step-up (65.4%) and MTX add-on (51.1%) therapy. This study characterizes contemporary patterns of ETN use in the CARRA Registry. Treatment was largely in keeping with American College of Rheumatology guidelines.
Sections du résumé
BACKGROUND
BACKGROUND
We aimed to characterize etanercept (ETN) use in juvenile idiopathic arthritis (JIA) patients enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry.
METHODS
METHODS
The CARRA Registry is a convenience cohort of patients with paediatric onset rheumatic diseases, including JIA. JIA patients treated with ETN for whom the month and year of ETN initiation were available were included. Patterns of ETN and methotrexate (MTX) use were categorized as follows: combination therapy (ETN and MTX started concurrently), step-up therapy (MTX started first and ETN added later), switchers (MTX started and then stopped when or before ETN started), MTX add-on (ETN started first and MTX added later), and ETN only (no MTX use). Data were described using parametric and non-parametric statistics as appropriate.
RESULTS
RESULTS
Two thousand thirty-two of the five thousand six hundred forty-one patients with JIA met inclusion criteria (74% female, median age at diagnosis 6.0 years [interquartile range 2.0, 11.0]. Most patients (66.9%) were treated with a non-biologic disease modifying anti-rheumatic drug (DMARD), primarily MTX, prior to ETN. There was significant variability in patterns of MTX use prior to starting ETN. Step-up therapy was the most common approach. Only 34.0% of persistent oligoarticular JIA patients continued treatment with a non-biologic DMARD 3 months or more after ETN initiation. ETN persistence overall was 66.3, 49.4, and 37.3% at 24, 36 and 48 months respectively. ETN persistence among spondyloarthritis patients (enthesitis related arthritis and psoriatic JIA) varied by MTX initiation pattern, with higher ETN persistence rates in those who initiated combination therapy (68.9%) and switchers/ETN only (73.3%) patients compared to step-up (65.4%) and MTX add-on (51.1%) therapy.
CONCLUSION
CONCLUSIONS
This study characterizes contemporary patterns of ETN use in the CARRA Registry. Treatment was largely in keeping with American College of Rheumatology guidelines.
Identifiants
pubmed: 34419107
doi: 10.1186/s12969-021-00625-y
pii: 10.1186/s12969-021-00625-y
pmc: PMC8380401
doi:
Substances chimiques
Immunosuppressive Agents
0
Tumor Necrosis Factor Inhibitors
0
Etanercept
OP401G7OJC
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
131Subventions
Organisme : Amgen
ID : (none)
Investigateurs
N Abel
(N)
K Abulaban
(K)
A Adams
(A)
M Adams
(M)
R Agbayani
(R)
J Aiello
(J)
S Akoghlanian
(S)
C Alejandro
(C)
E Allenspach
(E)
R Alperin
(R)
M Alpizar
(M)
G Amarilyo
(G)
W Ambler
(W)
E Anderson
(E)
S Ardoin
(S)
S Armendariz
(S)
E Baker
(E)
I Balboni
(I)
S Balevic
(S)
L Ballenger
(L)
S Ballinger
(S)
N Balmuri
(N)
F Barbar-Smiley
(F)
L Barillas-Arias
(L)
M Basiaga
(M)
K Baszis
(K)
M Becker
(M)
H Bell-Brunson
(H)
E Beltz
(E)
H Benham
(H)
S Benseler
(S)
W Bernal
(W)
T Beukelman
(T)
T Bigley
(T)
B Binstadt
(B)
C Black
(C)
M Blakley
(M)
J Bohnsack
(J)
J Boland
(J)
A Boneparth
(A)
S Bowman
(S)
C Bracaglia
(C)
E Brooks
(E)
M Brothers
(M)
A Brown
(A)
H Brunner
(H)
M Buckley
(M)
M Buckley
(M)
H Bukulmez
(H)
D Bullock
(D)
B Cameron
(B)
S Canna
(S)
L Cannon
(L)
P Carper
(P)
V Cartwright
(V)
E Cassidy
(E)
L Cerracchio
(L)
E Chalom
(E)
J Chang
(J)
A Chang-Hoftman
(A)
V Chauhan
(V)
P Chira
(P)
T Chinn
(T)
K Chundru
(K)
H Clairman
(H)
D Co
(D)
A Confair
(A)
H Conlon
(H)
R Connor
(R)
A Cooper
(A)
J Cooper
(J)
S Cooper
(S)
C Correll
(C)
R Corvalan
(R)
D Costanzo
(D)
R Cron
(R)
L Curiel-Duran
(L)
T Curington
(T)
M Curry
(M)
A Dalrymple
(A)
A Davis
(A)
C Davis
(C)
C Davis
(C)
T Davis
(T)
F De Benedetti
(F)
D De Ranieri
(D)
J Dean
(J)
F Dedeoglu
(F)
M DeGuzman
(M)
N Delnay
(N)
V Dempsey
(V)
E DeSantis
(E)
T Dickson
(T)
J Dingle
(J)
B Donaldson
(B)
E Dorsey
(E)
S Dover
(S)
J Dowling
(J)
J Drew
(J)
K Driest
(K)
Q Du
(Q)
K Duarte
(K)
D Durkee
(D)
E Duverger
(E)
J Dvergsten
(J)
A Eberhard
(A)
M Eckert
(M)
K Ede
(K)
B Edelheit
(B)
C Edens
(C)
C Edens
(C)
Y Edgerly
(Y)
M Elder
(M)
B Ervin
(B)
S Fadrhonc
(S)
C Failing
(C)
D Fair
(D)
M Falcon
(M)
L Favier
(L)
S Federici
(S)
B Feldman
(B)
J Fennell
(J)
I Ferguson
(I)
P Ferguson
(P)
B Ferreira
(B)
R Ferrucho
(R)
K Fields
(K)
T Finkel
(T)
M Fitzgerald
(M)
C Fleming
(C)
O Flynn
(O)
L Fogel
(L)
E Fox
(E)
M Fox
(M)
L Franco
(L)
M Freeman
(M)
K Fritz
(K)
S Froese
(S)
R Fuhlbrigge
(R)
J Fuller
(J)
N George
(N)
K Gerhold
(K)
D Gerstbacher
(D)
M Gilbert
(M)
M Gillispie-Taylor
(M)
E Giverc
(E)
C Godiwala
(C)
I Goh
(I)
H Goheer
(H)
D Goldsmith
(D)
E Gotschlich
(E)
A Gotte
(A)
B Gottlieb
(B)
C Gracia
(C)
T Graham
(T)
S Grevich
(S)
T Griffin
(T)
J Griswold
(J)
A Grom
(A)
M Guevara
(M)
P Guittar
(P)
M Guzman
(M)
M Hager
(M)
T Hahn
(T)
O Halyabar
(O)
E Hammelev
(E)
M Hance
(M)
A Hanson
(A)
L Harel
(L)
S Haro
(S)
J Harris
(J)
O Harry
(O)
E Hartigan
(E)
J Hausmann
(J)
A Hay
(A)
K Hayward
(K)
J Heiart
(J)
K Hekl
(K)
L Henderson
(L)
M Henrickson
(M)
A Hersh
(A)
K Hickey
(K)
P Hill
(P)
S Hillyer
(S)
L Hiraki
(L)
M Hiskey
(M)
P Hobday
(P)
C Hoffart
(C)
M Holland
(M)
M Hollander
(M)
S Hong
(S)
M Horwitz
(M)
J Hsu
(J)
A Huber
(A)
J Huggins
(J)
J Hui-Yuen
(J)
C Hung
(C)
J Huntington
(J)
A Huttenlocher
(A)
M Ibarra
(M)
L Imundo
(L)
C Inman
(C)
A Insalaco
(A)
A Jackson
(A)
S Jackson
(S)
K James
(K)
G Janow
(G)
J Jaquith
(J)
S Jared
(S)
N Johnson
(N)
J Jones
(J)
J Jones
(J)
J Jones
(J)
K Jones
(K)
S Jones
(S)
S Joshi
(S)
L Jung
(L)
C Justice
(C)
A Justiniano
(A)
N Karan
(N)
K Kaufman
(K)
A Kemp
(A)
E Kessler
(E)
U Khalsa
(U)
B Kienzle
(B)
S Kim
(S)
Y Kimura
(Y)
D Kingsbury
(D)
M Kitcharoensakkul
(M)
T Klausmeier
(T)
K Klein
(K)
M Klein-Gitelman
(M)
B Kompelien
(B)
A Kosikowski
(A)
L Kovalick
(L)
J Kracker
(J)
S Kramer
(S)
C Kremer
(C)
J Lai
(J)
J Lam
(J)
B Lang
(B)
S Lapidus
(S)
B Lapin
(B)
A Lasky
(A)
D Latham
(D)
E Lawson
(E)
R Laxer
(R)
P Lee
(P)
P Lee
(P)
T Lee
(T)
L Lentini
(L)
M Lerman
(M)
D Levy
(D)
S Li
(S)
S Lieberman
(S)
L Lim
(L)
C Lin
(C)
N Ling
(N)
M Lingis
(M)
M Lo
(M)
D Lovell
(D)
D Lowman
(D)
N Luca
(N)
S Lvovich
(S)
C Madison
(C)
J Madison
(J)
S Magni Manzoni
(SM)
B Malla
(B)
J Maller
(J)
M Malloy
(M)
M Mannion
(M)
C Manos
(C)
L Marques
(L)
A Martyniuk
(A)
T Mason
(T)
S Mathus
(S)
L McAllister
(L)
K McCarthy
(K)
K McConnell
(K)
E McCormick
(E)
D McCurdy
(D)
P Mc Curdy Stokes
(PMC)
S McGuire
(S)
I McHale
(I)
A McMonagle
(A)
C McMullen-Jackson
(C)
E Meidan
(E)
E Mellins
(E)
E Mendoza
(E)
R Mercado
(R)
A Merritt
(A)
L Michalowski
(L)
P Miettunen
(P)
M Miller
(M)
D Milojevic
(D)
E Mirizio
(E)
E Misajon
(E)
M Mitchell
(M)
R Modica
(R)
S Mohan
(S)
K Moore
(K)
L Moorthy
(L)
S Morgan
(S)
E Morgan Dewitt
(EM)
C Moss
(C)
T Moussa
(T)
V Mruk
(V)
A Murphy
(A)
E Muscal
(E)
R Nadler
(R)
B Nahal
(B)
K Nanda
(K)
N Nasah
(N)
L Nassi
(L)
S Nativ
(S)
M Natter
(M)
J Neely
(J)
B Nelson
(B)
L Newhall
(L)
L Ng
(L)
J Nicholas
(J)
R Nicolai
(R)
P Nigrovic
(P)
J Nocton
(J)
B Nolan
(B)
E Oberle
(E)
B Obispo
(B)
B O'Brien
(B)
T O'Brien
(T)
O Okeke
(O)
M Oliver
(M)
J Olson
(J)
K O'Neil
(K)
K Onel
(K)
A Orandi
(A)
M Orlando
(M)
S Osei-Onomah
(S)
R Oz
(R)
E Pagano
(E)
A Paller
(A)
N Pan
(N)
S Panupattanapong
(S)
M Pardeo
(M)
J Paredes
(J)
A Parsons
(A)
J Patel
(J)
K Pentakota
(K)
P Pepmueller
(P)
T Pfeiffer
(T)
K Phillippi
(K)
D Pires Marafon
(DP)
K Phillippi
(K)
L Ponder
(L)
R Pooni
(R)
S Prahalad
(S)
S Pratt
(S)
S Protopapas
(S)
B Puplava
(B)
J Quach
(J)
M Quinlan-Waters
(M)
C Rabinovich
(C)
S Radhakrishna
(S)
J Rafko
(J)
J Raisian
(J)
A Rakestraw
(A)
C Ramirez
(C)
E Ramsay
(E)
S Ramsey
(S)
R Randell
(R)
A Reed
(A)
A Reed
(A)
A Reed
(A)
H Reid
(H)
K Remmel
(K)
A Repp
(A)
A Reyes
(A)
A Richmond
(A)
M Riebschleger
(M)
S Ringold
(S)
M Riordan
(M)
M Riskalla
(M)
M Ritter
(M)
R Rivas-Chacon
(R)
A Robinson
(A)
E Rodela
(E)
M Rodriquez
(M)
K Rojas
(K)
T Ronis
(T)
M Rosenkranz
(M)
B Rosolowski
(B)
H Rothermel
(H)
D Rothman
(D)
E Roth-Wojcicki
(E)
K Rouster-Stevens
(K)
T Rubinstein
(T)
N Ruth
(N)
N Saad
(N)
S Sabbagh
(S)
E Sacco
(E)
R Sadun
(R)
C Sandborg
(C)
A Sanni
(A)
L Santiago
(L)
A Sarkissian
(A)
S Savani
(S)
L Scalzi
(L)
L Schanberg
(L)
S Scharnhorst
(S)
K Schikler
(K)
A Schlefman
(A)
H Schmeling
(H)
K Schmidt
(K)
E Schmitt
(E)
R Schneider
(R)
K Schollaert-Fitch
(K)
G Schulert
(G)
T Seay
(T)
C Seper
(C)
J Shalen
(J)
R Sheets
(R)
A Shelly
(A)
S Shenoi
(S)
K Shergill
(K)
J Shirley
(J)
M Shishov
(M)
C Shivers
(C)
E Silverman
(E)
N Singer
(N)
V Sivaraman
(V)
J Sletten
(J)
A Smith
(A)
C Smith
(C)
J Smith
(J)
J Smith
(J)
E Smitherman
(E)
J Soep
(J)
M Son
(M)
S Spence
(S)
L Spiegel
(L)
J Spitznagle
(J)
R Sran
(R)
H Srinivasalu
(H)
H Stapp
(H)
K Steigerwald
(K)
Y Sterba Rakovchik
(YS)
S Stern
(S)
A Stevens
(A)
B Stevens
(B)
R Stevenson
(R)
K Stewart
(K)
C Stingl
(C)
J Stokes
(J)
M Stoll
(M)
E Stringer
(E)
S Sule
(S)
J Sumner
(J)
R Sundel
(R)
M Sutter
(M)
R Syed
(R)
G Syverson
(G)
A Szymanski
(A)
S Taber
(S)
R Tal
(R)
A Tambralli
(A)
A Taneja
(A)
T Tanner
(T)
S Tapani
(S)
G Tarshish
(G)
S Tarvin
(S)
L Tate
(L)
A Taxter
(A)
J Taylor
(J)
M Terry
(M)
M Tesher
(M)
A Thatayatikom
(A)
B Thomas
(B)
K Tiffany
(K)
T Ting
(T)
A Tipp
(A)
D Toib
(D)
K Torok
(K)
C Toruner
(C)
H Tory
(H)
M Toth
(M)
S Tse
(S)
V Tubwell
(V)
M Twilt
(M)
S Uriguen
(S)
T Valcarcel
(T)
H Van Mater
(H)
L Vannoy
(L)
C Varghese
(C)
N Vasquez
(N)
K Vazzana
(K)
R Vehe
(R)
K Veiga
(K)
J Velez
(J)
J Verbsky
(J)
G Vilar
(G)
N Volpe
(N)
E von Scheven
(E)
S Vora
(S)
J Wagner
(J)
L Wagner-Weiner
(L)
D Wahezi
(D)
H Waite
(H)
J Walker
(J)
H Walters
(H)
T Wampler Muskardin
(TW)
L Waqar
(L)
M Waterfield
(M)
M Watson
(M)
A Watts
(A)
P Weiser
(P)
J Weiss
(J)
P Weiss
(P)
E Wershba
(E)
A White
(A)
C Williams
(C)
A Wise
(A)
J Woo
(J)
L Woolnough
(L)
T Wright
(T)
E Wu
(E)
A Yalcindag
(A)
M Yee
(M)
E Yen
(E)
R Yeung
(R)
K Yomogida
(K)
Q Yu
(Q)
R Zapata
(R)
A Zartoshti
(A)
A Zeft
(A)
R Zeft
(R)
Y Zhang
(Y)
Y Zhao
(Y)
A Zhu
(A)
C Zic
(C)
Informations de copyright
© 2021. The Author(s).
Références
Ann Rheum Dis. 2015 Jul;74(7):1379-86
pubmed: 24641940
Rheumatology (Oxford). 2016 Sep;55(9):1556-65
pubmed: 26732349
Arthritis Res Ther. 2018 Dec 27;20(1):285
pubmed: 30587248
Rheumatology (Oxford). 2013 Apr;52(4):712-7
pubmed: 23267169
J Rheumatol. 2016 Apr;43(4):816-24
pubmed: 26932344
Arthritis Rheum. 2008 May;58(5):1496-504
pubmed: 18438876
Rheumatology (Oxford). 2020 Sep 1;59(9):2287-2298
pubmed: 31846042
J Rheumatol. 2004 Feb;31(2):390-2
pubmed: 14760812
JAMA. 2011 Dec 7;306(21):2340-7
pubmed: 22056397
Qual Life Res. 2015 Sep;24(9):2195-208
pubmed: 25715946
Arthritis Care Res (Hoboken). 2019 Jun;71(6):717-734
pubmed: 31021516
Semin Arthritis Rheum. 2017 Apr;46(5):584-593
pubmed: 27914689
Arthritis Care Res (Hoboken). 2014 Jul;66(7):1063-72
pubmed: 24339215
Arthritis Care Res (Hoboken). 2011 Apr;63(4):465-82
pubmed: 21452260
Ann Rheum Dis. 2013 Dec;72(12):1983-8
pubmed: 23256951
Pediatr Rheumatol Online J. 2017 Apr 17;15(1):30
pubmed: 28416023
Arthritis Res Ther. 2019 May 23;21(1):125
pubmed: 31122296
Arthritis Rheum. 1997 Jul;40(7):1202-9
pubmed: 9214419
Arthritis Rheum. 2013 Oct;65(10):2499-512
pubmed: 24092554
N Engl J Med. 2000 Mar 16;342(11):763-9
pubmed: 10717011
Expert Opin Biol Ther. 2013 Nov;13(11):1623-30
pubmed: 24070010
Joint Bone Spine. 2014 Mar;81(2):112-7
pubmed: 24210707